Online citations, reference lists, and bibliographies.
← Back to Search

Dementia In Parkinsonism

S. Daniel, F. cruz-Sánchez, A. J. Lees
Published 1997 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
This paper references
10.1212/WNL.41.8.1178
Rapidly progressive dementia in a patient with the Lewy body variant of Alzheimer's disease
T. P. Armstrong (1991)
10.1111/j.1471-4159.1980.tb07883.x
Hippocampal Free Amino Acids in Alzheimer's Disease
I. Tarbit (1980)
depressed patients with Parkinson's disease
R Mayeux (1986)
Gene dose of apolipoprotein E
AD Roses (1993)
The influence of apolipoprotein E genotype on senile dementia of the Alzheimer and Lewy body types
CR Harrington (1994)
10.1016/S0140-6736(94)92511-9
Risperidone for hallucinations in levodopa-treated Parkinson's disease patients
G. Meco (1994)
10.1093/OXFORDJOURNALS.BMB.A072100
The cholinergic hypothesis--ten years on.
E. Perry (1986)
10.1038/365393A0
The D4 and schizophrenia
L. Iversen (1993)
10.1017/S0317167100029140
Regional metal concentrations in Parkinson's disease, other chronic neurological diseases, and control brains.
R. Uitti (1989)
10.1111/j.1600-0447.1985.tb01268.x
Tolerability and therapeutic effect of clozapine
U. Juul Povlsen (1985)
Comparison of conventional and Sinemet CR on the sleep of parkinsonian patients
PA Nausieda (1994)
Dementia associated with cortical Lewy bodies (Byrne et aI., 1991) - Lewy body dementia (Sima et aI., 1986) - Diffuse cortical Lewy body disease
Kosaka (1987)
triggers, and the development of therapeutic strategies targeted at the underlying causes of both diseases
H Arai (1984)
10.1212/WNL.41.4.479
The Consortium to Establish a Registry for Alzheimer's Disease (CERAD)
S. S. Mirra (1991)
10.1212/WNL.45.9.1768
Ubiquitin-positive CA2/3 neurites in hippocampus coexist with cortical Lewy bodies
H. Kim (1995)
10.1212/WNL.45.3.482
Cytochrome C Oxidase in Alzheimer's Disease Brain
W. Parker (1995)
10.1097/00002826-199201001-00054
NOVEL SEROTONERGIC MECHANISMS AND CLINICAL EXPERIENCE WITH NEFAZODONE
R. Fontaine (1992)
Influence of apolipoprotein E genotype on senile dementia of the Alzheimer and Lewy body types. Significance for etiological theories of Alzheimer's disease.
C. Harrington (1994)
10.1126/SCIENCE.1925564
A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease.
J. Murrell (1991)
disease: a clinical and pathological entity. Neurology
AJ Hughes (1992)
Increased nigraI iron content in post-mortem parkinsonian brain
DT Dexter (1987)
Intellectual and memory function in parkinsonian and non-parkinsonian patients treated with L-dopa.
Donnelly Ef (1973)
10.1192/BJP.165.3.324
The clinical diagnosis and misdiagnosis of senile dementia of Lewy body type (SDLT).
I. McKeith (1994)
10.1136/jnnp.50.6.825
Glutamatergic denervation in Alzheimer's disease--a cautionary note.
A. Procter (1987)
10.1017/S0317167100037185
Lewy body dementia without Alzheimer changes.
A. Sima (1986)
Brain alpha-ketoglutarate dehydrogenase complex activity in Alzheimer's disease.
F. Mastrogiacomo (1993)
10.1097/00002093-198802030-00069
DOUBLE‐BLIND STUDY WITH PHOSPHATIDYLSERINE IN PARKINSONIAN PATIENTS WITH SENILE DEMENTIA OF ALZHEIMER'S TYPE (SDAT)
E. Fünfgeld (1989)
10.1212/WNL.34.7.939
Clinical diagnosis of Alzheimer's disease
G. Mckhann (1984)
10.1136/jnnp.37.2.121
The `subcortical dementia' of progressive supranuclear palsy
M. Albert (1974)
10.1111/j.1600-0404.1988.tb03668.x
Clozapine treatment of drug‐induced psychotic symptoms in late stages of Parkinson's disease
K. Østergaard (1988)
10.1097/00005072-196207000-00012
CONCENTRIC HYALINE INCLUSION BODY FORMATION IN MENTAL DISEASE ANALYSIS OF TWENTY‐SEVEN CASES
J. S. Woodard (1962)
10.1007/BF00867426
Progression of motor and cognitive impairment in Parkinson's disease
E. Palazzini (2004)
Ondansetron, a 5-HT3 antagonist for visual hallucinations and paranoid delusional disorder associated with chronic L-DOPA therapy in advanced Parkinson's disease.
J. Zoldan (1996)
10.1159/000315546
Senile dementia of Lewy body type and Alzheimer type are biochemically distinct in terms of paired helical filaments and hyperphosphorylated tau protein.
C. Harrington (1994)
10.1136/jnnp.23.1.56
A RATING SCALE FOR DEPRESSION
M. Hamilton (1960)
10.1016/0022-510X(85)90156-X
Superoxide dismutase isoenzymes in normal brains and in brains from patients with dementia of Alzheimer type
S. Marklund (1985)
10.1097/00005072-199305000-00001
Pathology and Biology of the Lewy Body
M. Pollanen (1993)
Effects of posteroventral pallidotomy on Parkinson's disease.
M. Dogali (1996)
10.1136/jnnp.34.5.502
Psychiatric aspects in Parkinsonism treated with L-dopa
A. Damasio (1971)
10.1212/WNL.45.4.672
The influence of depression on cognition in Parkinson's disease
A. I. Troster (1995)
10.1097/01.nnn.0000412264.92285.80
Lewy body disease.
L. Hansen (1992)
Gudelsky GA (1989a) Melperone and clozapine
HY Meltzer (1989)
Clinical and pathological features of diffuse Lewy body disease (Lewy body dementia)
WRG Gibb (1985)
10.1016/0006-8993(94)91670-5
Selective increase in lipid peroxidation in the inferior temporal cortex in Alzheimer's disease
A. M. Palmer (1994)
10.1073/PNAS.90.5.1977
Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease.
W. Strittmatter (1993)
10.1159/000107037
A comparative study of attentional deficits in senile dementias of Alzheimer and lewy body types
A. Sahgal (1992)
10.1016/0006-8993(86)90611-6
Density and distribution of NMDA receptors in the human hippocampus in Alzheimer's disease
J. Geddes (1986)
10.1016/0304-3940(94)90190-2
Senile dementia of the Lewy body type has an apolipoprotein E ε4 allele frequency intermediate between controls and Alzheimer's disease
J. Hardy (1994)
10.1073/PNAS.89.16.7620
Regional mapping of prion proteins in brain.
A. Taraboulos (1992)
10.1016/0304-3940(77)90070-2
A cholinergic connection between normal aging and senile dementia in the human hippocampus
E. Perry (1977)
10.1016/0022-510X(91)90251-2
Quantitative neuropathological study of Alzheimer-type pathology in the hippocampus: Comparison of senile dementia of Alzheimer type, senile dementia of Lewy body type, Parkinson's disease and non-demented elderly control patients
P. Ince (1991)
The clinicopathologic spectrum of Lewy body disease.
M. Mark (1996)
10.1212/WNL.25.8.701
Parkinsonism: Effects of levodopa treatment on concept formation
F. P. Bowen (1975)
Serotonin receptor subtypes in depression: evidence from studies in neuroendocrine regulation.
P. Cowen (1993)
10.1016/0306-4492(77)90004-1
Distribution of catecholamines in the cattle tick Boophilus microplus.
K. Binnington (1977)
10.1111/j.1471-4159.1990.tb02325.x
Mitochondrial Complex I Deficiency in Parkinson's Disease
A. H. V. Schapira (1989)
Dementia and Parkinson's
EJ Byrne (1987)
Segregation of a missense mutation
A Goate (1991)
10.1002/ANA.410260403
Midbrain dopaminergic cell loss in parkinson's disease: Computer visualization
D. German (1989)
10.1016/0006-8993(88)90587-2
Regional changes in [3H]d-aspartate and [3H]TCP binding sites in Alzheimer's disease brains
M. Simpson (1988)
10.1002/ANA.410350113
Alzheimer's disease and Lewy body disease: A comparative clinicopathological study
C. Lippa (1994)
10.1176/AJP.152.1.122
Fluoxetine and extrapyramidal side effects.
D. Coulter (1995)
10.1002/MDS.870050308
A controlled trial of piracetam in intellectually impaired patients with Parkinson's disease
M. Sano (1990)
10.1192/BJP.157.1.81
Psychiatric phenomena in Alzheimer's disease. III: Disorders of mood.
A. Burns (1990)
10.1136/jnnp.53.7.597
Cognitive impairments and depression in Parkinson's disease: a follow up study.
S. Starkstein (1990)
10.1212/WNL.38.10.1553
Does an inhibitory action of levodopa contribute to motor fluctuations?
J. Nutt (1988)
10.1016/0306-4522(90)90246-Z
Alzheimer's disease: Changes in hippocampal N-methyl-d-aspartate, quisqualate, neurotensin, adenosine, benzodiazepine, serotonin and opioid receptors—an autoradiographic study
K. Jansen (1990)
Prolonged post-ictal
LP Karper (1992)
The non - cognitive features of dementia
H Allen (1995)
10.1007/978-3-7091-6846-2_10
Pathology of familial Alzheimer's disease with Lewy bodies.
T. Revesz (1997)
10.1016/0197-4580(94)90032-9
Morphological criteria for the recognition of Alzheimer's disease and the distribution pattern of cortical changes related to this disorder
H. Braak (1994)
10.1192/BJP.162.3.385
The Lewy-body variant of Alzheimer's disease. Clinical and pathological findings.
Hans Förstl (1993)
Diffuse type of Lewy body disease: progressive dementia with abundant cortical Lewy bodies and senile changes of varying degree--a new disease?
K. Kosaka (1984)
10.1093/BRAIN/109.5.987
Visuospatial function in Parkinson's disease.
R. Brown (1986)
10.1136/jnnp.50.3.357
Glutamate deficits in Alzheimer's disease
A. Cross (1987)
A pathological study of the association between Lewy body disease and Alzheimer's disease.
W. Gibb (1990)
Apolipoprotein E-epsilon 4 allele and Alzheimer's disease.
G. Lucotte (1993)
10.1136/jnnp.49.4.381
Depression in Parkinson's disease: a quantitative and qualitative analysis.
A. M. Gotham (1986)
10.1097/00005053-197704000-00006
LEVODOPA, PARKINSONISM, AND RECENT MEMORY
R. Halgin (1977)
10.1212/WNL.44.9.1756
The effect of deprenyl and tocopherol on cognitive performance in early untreated Parkinson's disease
K. Kieburtz (1994)
10.1016/0197-4580(87)90005-4
Sodium-dependent glutamate binding in senile dementia
E. Mcgeer (1987)
Lewy body and Parkinson's disease
C Betard (1994)
10.1017/S0033291700020468
Factors affecting survival in Alzheimer's disease.
A. Burns (1991)
A comparison of nefazodone, imipramine, and placebo in patients with moderate to severe depression.
J. Feighner (1989)
10.1176/AJP.147.4.503
Weight gain associated with clozapine.
S. Cohen (1990)
10.1002/MDS.870100325
Does fluoxetine aggravate Parkinson's disease? A pilot prospective study
J. L. Montastruc (1995)
10.1002/ANA.410350107
Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease
D. Dexter (1994)
10.1016/0304-3940(92)90608-A
Quantification of βA4 protein deposition in the medial temporal lobe: A comparison of Alzheimer's disease and senile dementia of the Lewy body type
S. Gentleman (1992)
10.1001/ARCHNEUR.1969.00480160015001
Treatment of parkinsonism with levodopa.
M. Yahr (1969)
10.1212/WNL.37.8.1371
Fluctuations in plasma dopamine level impair memory in Parkinson's disease
S. Huber (1987)
10.1080/01688639308402591
Incidental and intentional recall in Parkinson's disease: an account based on diminished attentional resources.
J. Cooper (1993)
10.1136/jnnp.52.2.185
Cortical Lewy body dementia: clinical features and classification.
W. Gibb (1989)
10.1097/00005072-199101000-00007
Hippocampal Lesions in Dominantly Inherited Alzheimer's Disease
R. Struble (1991)
10.1016/0022-510X(92)90137-A
Dopa-responsive dystonia with depigmentation of the substantia nigra and formation of Lewy bodies
J. Olsson (1992)
10.1212/WNL.43.9.1690
Antecedent clinical features associated with dementia in Parkinson's disease
Y. Stern (1993)
10.1097/00002093-198701000-00005
gamma-Glutamyltransferase: normal cortical levels in Alzheimer disease.
E. Mcgeer (1987)
Clinical management of clozapine
R Holzbach (1992)
Adverse consequences of fluoxetine-MAOI combination therapy.
J. Feighner (1990)
postsynaptic glutamatergic function in Alzheimer's disease
RF Cowburn (1989)
Parkinson's disease: a disorder due to nigraI glutathione deficiency
T Perry (1982)
10.1073/PNAS.90.17.7951
Apoptosis is induced by beta-amyloid in cultured central nervous system neurons.
D. Loo (1993)
Lewy body disease with and without dementia: a clinicopathological study of 35 cases.
K. Kosaka (1988)
10.1016/0304-3940(82)90390-1
Parkinson's disease: A disorder due to nigral glutathione deficiency?
T. Perry (1982)
10.1002/ANA.410220207
Aminergic systems in Alzheimer's disease and Parkinson's disease
R. Damato (1987)
10.1007/BF00688061
Progressive supranuclear palsy with Lewy bodies
H. Mori (2004)
10.1007/BF00442555
D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics
L. Farde (2004)
10.1055/S-0028-1094449
Clozapine and the dopamine hypothesis of schizophrenia, a critical appraisal.
H. Bürki (1975)
10.1016/S0140-6736(94)92961-0
Apolipoprotein E genes in Lewy body and Parkinson's disease
R. Benjamin (1994)
10.1126/science.7638622
Candidate gene for the chromosome 1 familial Alzheimer's disease locus
E. Levy-Lahad (1995)
10.1016/0920-9964(92)90177-7
EEG alterations in patients treated with clozapine in relation to plasma levels
C. Haring (1992)
10.1111/j.1471-4159.1989.tb11759.x
A Selective Increase in Particulate Superoxide Dismutase Activity in Parkinsonian Substantia Nigra
H. Saggu (1989)
10.1056/NEJM199307153290312
Clozapine--deciphering the risks.
S. Gerson (1993)
10.1126/science.7638621
A familial Alzheimer's disease locus on chromosome 1
E. Levy-Lahad (1995)
10.1136/jnnp.52.6.709
Diffuse Lewy body disease: clinical features in 15 cases.
E. Byrne (1989)
10.1016/S0140-6736(95)92404-3
Effect of GPi pallidotomy on motor function in Parkinson's disease
A. Lozano (1995)
familial cases are due to mutations in a recently cloned gene on chromosome
T. Revesz (1995)
10.1002/ANA.410330515
Effects of terguride, a partial D2 agonist, on MPTP‐lesioned parkinsonian cynomolgus monkeys
T. Akai (1993)
10.1016/0304-3940(91)90478-C
Entorhinal neurofibrillary tangles in Alzheimer disease with Lewy bodies
L. Hansen (1991)
10.1016/0304-3940(80)90220-7
Coenzyme a-acetylating enzymes in Alzheimer's disease: Possible cholinergic ‘compartment’ of pyruvate dehydrogenase
E. Perry (1980)
10.1007/BF00308809
Neuropathological stageing of Alzheimer-related changes
H. Braak (2004)
10.1016/0140-6736(92)90467-H
Clozapine, single photon emission tomography, and the D2 dopamine receptor blockade hypothesis of schizophrenia
L. Pilowsky (1992)
10.1006/BRCG.1995.1255
Acetylcholine and Hallucinations - Disease-Related Compared to Drug-Induced Alterations in Human Consciousness
E. Perry (1995)
10.1093/BRAIN/118.6.1447
Ubiquitin-positive degenerating neurites in the brainstem in Parkinson's disease.
W. Gai (1995)
10.1097/00001756-199403000-00002
Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease.
E. Perry (1994)
10.1016/0304-3940(93)90590-H
Neuropathological staging of Alzheimer lesions and intellectual status in Alzheimer's and Parkinson's disease patients
C. Bancher (1993)
10.1212/WNL.41.9.1402
Hippocampal degeneration differentiates diffuse Lewy body disease (DLBD) from Alzheimer's disease
D. Dickson (1991)
10.1097/00005072-199311000-00012
Plaque‐Only Alzheimer Disease is Usually the Lewy Body Variant, and Vice Versa
L. Hansen (1993)
10.1016/0304-3940(87)90034-6
Region-specific loss of glutamate innervation in Alzheimer's disease
J. Hardy (1987)
10.1016/0022-510X(90)90056-S
Postmortem changes in mitochondrial respiratory enzymes in brain and a preliminary observation in Parkinson's disease
Y. Mizuno (1990)
10.1016/0028-3932(94)00071-9
Parkinsonian patients without dementia or depression do not suffer from bradyphrenia as indexed by performance in mental rotation tasks with and without advance information
Melissa E. Duncombe (1994)
10.1111/j.1471-4159.1990.tb08814.x
Decreased Ferritin Levels in Brain in Parkinson's Disease
D. Dexter (1990)
Chronic treatment of c1ozapine, unlike haloperidol, does not induce changes in D-2 receptor function in the rat
NMJ Rupniak (1985)
10.1017/CBO9780511601187
Dementia With Lewy Bodies: Clinical, Pathological and Treatment Issues
J. Cummings (1996)
10.1002/ANA.410210403
Amino acids, glutathione, and glutathione transferase activity in the brains of patients with Alzheimer's disease
T. Perry (1987)
10.1016/0304-3940(86)90190-4
Excitatory amino acid-releasing and cholinergic neurones in Alzheimer's disease
A. M. Palmer (1986)
10.1016/0197-4580(81)90032-4
Neurochemical activities in human temporal lobe related to aging and Alzheimer-type changes
E. Perry (1982)
10.1097/00005053-199001000-00004
Clinical Assessment of Irritability, Aggression, and Apathy in Huntington and Alzheimer Disease
A. Burns (1990)
10.1136/jnnp.58.1.51
Which factors predict cognitive decline in Parkinson's disease?
D. Caparros-Lefebvre (1995)
10.1136/jnnp.57.4.416
Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups.
(1994)
10.1016/0197-4580(87)90122-9
A correlative study on hippocampal cation shifts and amino acids and clinico-pathological data in Alzheimer's disease
J. B. Gramsbergen (1987)
10.1016/0197-4580(86)90003-5
Senile Dementia and Alzheimer's disease: Lack of changes of the cortical content of Quinolinic Acid
F. Moroni (1986)
10.1016/S0140-6736(94)90966-0
Lewy bodies and response to tacrine in Alzheimer's disease
R. Lévy (1994)
10.1017/S0033291700038459
Clinical and neuropathological correlates of depression in Alzheimer's disease.
Hans Förstl (1992)
10.1097/00002826-199502000-00005
Remoxipride in Parkinson's disease: differential response in patients with dyskinesias fluctuations versus psychosis.
A. Lang (1995)
PD-patient becomes clinically demented. Most studies agree that age and/or late onset of parkinsonian symptoms are the main predictive factors for mental deterioration in PD (Hietanen and Teravainen
F. Valldeoriola (1988)
10.1016/S0140-6736(94)92114-8
Risperidone in Parkinson's disease
B. Ford (1994)
10.1002/ANA.410360305
Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia
J. Sian (1994)
10.1016/0304-3940(89)90441-2
Loss of glycine-dependent radioligand binding to the N-methyl-d-aspartate-phencyclidine receptor complex in patients with Alzheimer's disease
A. Procter (1989)
10.1016/0022-510X(71)90178-X
Monoamines in the human neostriatum: topographic distribution in normals and in Parkinson's disease and their role in akinesia, rigidity, chorea, and tremor.
S. Fahn (1971)
10.1136/jnnp.52.1.67
Anti-ubiquitin immunocytochemistry is more sensitive than conventional techniques in the detection of diffuse Lewy body disease.
G. Lennox (1989)
10.1016/0165-6147(92)90025-2
Molecular biology of dopamine receptors.
D. Sibley (1992)
Late cognitive changes in Parkinson's disease with an emphasis on dementia.
E. Mohr (1995)
Alzheimer's disease patients
P Duffy (1988)
Cortical Lewy body disease: an alternative view
EJ Byrne (1995)
Drug therapy-clozapine : a novel antipsychotic agent
R. Baldessarini (1991)
L-Dopa and sleep in depressed patients
D Fram (1970)
10.1007/BF02312293
Brain quinolinic acid in Alzheimer's dementia
E. Sofic (1989)
10.1016/0006-8993(86)90213-1
The effects of acute intraseptal injection of haloperidol in vivo on hippocampal cholinergic function in the mouse
T. Durkin (1986)
10.1017/S0317167100027141
Treatment of dopaminomimetic psychosis in Parkinson's disease with electroconvulsive therapy.
T. Hurwitz (1988)
10.1016/0006-8993(84)90164-1
[3H]Kainic acid binding and choline acetyltransferase activity in alzheimer's dementia
B. Pearce (1984)
10.1177/089198879400700207
The Earliest Signs of Alzheimer's Disease
G. Oppenheim (1994)
10.1073/PNAS.91.1.380
Topography of a binding site for small amnestic peptides deduced from structure-activity studies: relation to amnestic effect of amyloid beta protein.
J. Flood (1994)
10.1192/S0007125000296906
Clozapine-associated agranulocytosis: risk and aetiology.
P. Krupp (1992)
10.1007/BF02260906
Brain gamma-aminobutyrate aminotransferase (GABA-T) and monoamine oxidase (MAO) in patients with Alzheimer's disease
Fathi Mohamed Sherif (1992)
10.1038/375754A0
Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
R. Sherrington (1995)
Nefazodone: preclinical pharmacology of a new antidepressant.
A. S. Eison (1990)
10.1136/pgmj.68.801.528
Alzheimer's disease.
M. Rossor (1993)
10.1016/0028-3908(91)90160-D
Trimipramine: Pharmacological reevaluation and comparison with clozapine
G. Gross (1991)
Genetic and molecular advances in Alzheimer's disease.
M. Mullan (1993)
Biochemical fundamentals of Parkinson's disease.
P. Riederer (1988)
10.1136/bmj.299.6690.3-a
Psychiatric aspects of Parkinson's disease.
R. Baldwin (1989)
10.1111/j.1600-0404.1994.tb02676.x
Frontal dysfunction in early Parkinson's diseases
E. Farina (1994)
Apolipoprotein E genes
R Benjamin (1994)
10.1038/sj.npp.1380237
Plasma Clozapine Levels and the Treatment of L-DOPA-Induced Psychosis in Parkinson's Disease
H. Meltzer (1995)
Alzheimer's disease and Lewy body disease: a comparative clinicopathological study [published erratum appears in Ann Neurol
CF Lippa (1994)
10.1111/j.1471-4159.1989.tb07264.x
Increased Nigral Iron Content and Alterations in Other Metal Ions Occurring in Brain in Parkinson's Disease
D. Dexter (1989)
Dopamine receptor sequences. Therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4.
P. Seeman (1992)
Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells.
N. Buckley (1989)
10.1176/AJP.135.6.669
Levodopa-induced psychosis: a kindling phenomenon.
C. Moskovitz (1978)
10.1001/JAMA.1970.03170290061017
Intellectual changes associated with levodopa therapy.
M. Meier (1970)
10.1002/GPS.930080707
Idiopathic clouding of consciousness—do the patients have cortical lewy body disease?
C. Ballard (1993)
10.1016/S0140-6736(94)92347-7
Oxidative damage in neurodegenerative disease
Peter Jenner (1994)
10.1212/WNL.44.3_PART_1.544
Clozapine: a 2-year open trial in Parkinson's disease patients with psychosis.
S. Factor (1994)
10.1002/ANA.410360510
Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease
P. Mecocci (1994)
10.1002/MDS.870070205
Clozapine prevents recurrence of psychosis in Parkinson's disease
S. Factor (1992)
10.1002/MDS.870080317
Modulatory effect of clozapine on levodopa response in parkinson's disease: A preliminary study
G. G. Arevalo (1993)
10.1212/WNL.36.8.1130
Parkinson's disease with depression
J. Santamaria (1986)
10.1136/bmj.305.6855.673
Neuroleptic sensitivity in patients with senile dementia of Lewy body type.
I. McKeith (1992)
clozapine on dopamine (J receptor blockade in the limbic system rather than in the basal ganglia
F. Valldeoriola (1981)
The development of new antipsychotic drugs: towards a new strategy
PAJ Jansen (1987)
A marker of oxyradical-mediated DNA damage (8-hydroxy-2'deoxyguanosine) is increased in nigro-striatum of Parkinson's disease
JR Sanchezramos (1994)
Comparison of the severity of neuropathologic changes in familial and sporadic Alzheimer's disease.
D. Nochlin (1993)
10.1016/0306-4522(93)90240-G
Serotoninergic terminal transporters are differentially affected in Parkinson's disease and progressive supranuclear palsy: An autoradiographic study with [3H]citalopram
G. Chinaglia (1993)
Risperidone: clinical safety and efficacy in schizophrenia.
R. Borison (1992)
10.1016/0303-8467(94)00060-J
‘Lewy body disease’: clinico-pathological correlations in 18 consecutive cases of Parkinson's disease with and without dementia
R. Vos (1995)
10.1136/jnnp.58.6.756-a
Lewy body dysphagia.
M. Jackson (1995)
10.1017/S031716710004124X
Fluoxetine and selegiline--lack of significant interaction.
C. Waters (1994)
10.1097/00002093-199040300-00002
Alzheimer Disease and the Dementia of Parkinson Disease: Comparative Investigations
M. Mahler (1990)
10.1111/j.1471-4159.1983.tb08102.x
Striatal GABAergic Neuronal Activity Is Not Reduced in Parkinson's Disease
T. Perry (1983)
Psychiatric disturbances in Parkinson's disease.
G. Celesia (1972)
10.1111/j.1471-4159.1990.tb03162.x
Evidence of a Monoaminergic‐Cholinergic Imbalance Related to Visual Hallucinations in Lewy Body Dementia
E. Perry (1990)
10.1016/0091-3057(88)90217-1
Multiple and complex effects of buspirone on central dopaminergic system
S. Algeri (1988)
Noncognitive neuropsychiatric syndromes in alzheimer’s disease
J. Cummings (1990)
Cognitive impairments associated with Parkinson's disease and other movement disorders
FJ Pirozzolo (1993)
10.1038/NG0892-345
A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N–terminus of β–amyloid
M. Mullan (1992)
10.1192/S0007125000296888
PET analysis indicates atypical central dopamine receptor occupancy in clozapine-treated patients.
L. Farde (1992)
10.1002/MDS.870050404
Sleep disorders and sleep effect in Parkinson's disease
S. Factor (1990)
10.1001/ARCHPSYC.1989.01810030049007
Reduction of prefrontal cortex glucose metabolism common to three types of depression.
L. Baxter (1989)
10.1002/ANA.410240518
Dementia, parkinsonism, and motor neuron disease: Neurochemical and neuropathological correlates
J. Gilbert (1988)
10.1093/AGEING/18.1.11
The prevalence and aetiology of long-term L-dopa side-effects in elderly parkinsonian patients.
J. Wilson (1989)
10.1016/S0140-6736(88)90986-5
NEUROLEPTIC MALIGNANT SYNDROME AFTER CLOZAPINE PLUS CARBAMAZEPINE
T. Muller (1988)
10.1128/JVI.65.9.4759-4768.1991
Neuropathological changes in scrapie and Alzheimer's disease are associated with increased expression of apolipoprotein E and cathepsin D in astrocytes.
J. Diedrich (1991)
Depression in Parkinson's disease: a psychosocial viewpoint.
R. Brown (1995)
10.1002/CNCR.2820690533
Extrapyramidal reaction to ondansetron
J. R. Halperin (1992)
Mode of onset and prognosis in Parkinson's disease
AH Rajput (1992)
disease: report of the NINCDS-ADRDA work group
Y Namba (1991)
10.1111/j.1471-4159.1990.tb05809.x
Anatomic and Disease Specificity of NADH CoQ1 Reductase (Complex I) Deficiency in Parkinson's Disease
A. Schapira (1990)
10.1212/WNL.31.6.645
Depression, intellectual impairment, and Parkinson disease
R. Mayeux (1981)
10.1111/j.1600-0404.1994.tb01677.x
Clozapine in the treatment of tremor in Parkinson's disease
E. Jansen (1994)
Dementia and neuropathology in Lewy body disease.
K. Kosaka (1993)
10.1515/REVNEURO.1993.4.1.1
The Genetics of Parkinson's Disease
L. Golbe (1993)
10.1002/ANA.410350212
An immunohistochemical study on α‐ketoglutarate dehydrogenase complex in Parkinson's disease
Y. Mizuno (1994)
10.1136/BMJ.305.6862.1160-C
Diarrhoea during treatment with clozapine.
M. Launer (1992)
10.1016/0140-6736(93)90327-D
Ondansetron for hallucinosis in advanced Parkinson's disease
J. Zoldan (1993)
10.1001/ARCHNEUR.1986.00520050094034
Dementia with cerebral Lewy bodies. A mesocortical dopaminergic defect?
D. E. Eggertson (1986)
10.1002/ANA.410170505
An immunochemical study of the pyruvate dehydrogenase deficit in Alzheimer's disease brain
K. Rex Sheu (1985)
Apolipoprotein-E epsilon-4 is associated with increased neurofibrillary pathology in the Lewy body variant of Alzheimer's disease.
L. Hansen (1994)
Diffuse Lewy body disease. Neuropathological and biochemical studies of six patients.
D. Dickson (1987)
10.1016/0165-1781(79)90062-3
Neuroleptic, antimuscarinic, and antiadrenergic activity of chlorpromazine, thioridazine, and their metabolites
B. Cohen (1979)
10.1016/S0304-3940(96)12429-0
Abnormal, ubiquitinated cortical neurites in patients with diffuse Lewy body disease
A. Pellisé (1996)
10.1111/j.1471-4159.1989.tb09150.x
Transition Metals, Ferritin, Glutathione, and Ascorbic Acid in Parkinsonian Brains
P. Riederer (1989)
serotonin S2 receptors in Alzheimer-type dementia
AI Cross (1987)
Anticholinergic medications are likely to produce confusion and disorientation, and aggravate memory performance, so they should be tapered and discontinued in demented patients
cognitive decline (1982)
10.1212/WNL.40.10.1529
Variable expression of Parkinson's disease
J. Jankovic (1990)
10.1002/MDS.870070410
Diffuse lewy body disease presenting with supranuclear gaze palsy, parkinsonism, and dementia: A case report
V. M. D. de Bruin (1992)
10.1038/349704A0
Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease
A. Goate (1991)
10.1176/AJP.147.2.217
Anxiety disorders in patients with Parkinson's disease.
M. Stein (1990)
10.1007/BF00887816
Diffuse Lewy body disease as substrate of primary lateral sclerosis
J. A. Hainfellner (2004)
10.1016/0006-8993(94)91709-4
Synapse alterations in the hippocampal-entorhinal formation in Alzheimer's disease with and without Lewy body disease
K. Wakabayashi (1994)
10.1212/WNL.31.11.1415
Kluver‐Bucy Syndrome in Pick disease
J. Cummings (1981)
10.1212/WNL.45.4.753
Stereotactic ventral pallidotomy for Parkinson's disease
M. Dogali (1995)
10.1161/01.STR.19.1.125
Post-stroke depression and lesion location.
R. Robinson (1988)
Cortical Lewy bodies in Alzheimer's disease.
A. M. Kazee (1995)
10.1097/00004714-199302000-00004
A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.
G. Chouinard (1993)
10.1016/0022-510X(91)90193-B
Cortical serotonin-S2 receptor binding in Lewy body dementia, Alzheimer's and Parkinson's diseases
A. Cheng (1991)
Cholinergic-dependent deficits in Parkinson's disease
B Dubois (1987)
Lewy bodies. Dementia
JA Court (1993)
The clozapine antagonism to 5-HT2 receptors was suggested to be the basis for its efficacy in the treatment of levodopa-induced psychosis
Seeman (1993)
10.1016/0304-3940(94)90541-X
Lewy bodies in Alzheimer's disease in which the primary lesion is a mutation in the amyloid precursor protein
J. Hardy (1994)
10.1016/0304-3940(92)90408-Y
Familial Alzheimer's disease with the amyloid precursor protein position 717 mutation and sporadic Alzheimer's disease have the same cytoskeletal pathology
P. Lantos (1992)
10.1016/0304-3940(85)90078-3
Glutathione peroxidase activity in Parkinson's disease brain
S. Kish (1985)
10.1126/SCIENCE.2858129
Alterations in L-glutamate binding in Alzheimer's and Huntington's diseases.
J. T. Greenamyre (1985)
10.1007/BF00428197
Effect of serotonin antagonism in schizophrenia: A pilot study with setoperone
D. L. Ceulemans (2004)
10.1001/ARCHNEUR.1971.00490020063007
Personality (MMPI) and cognitive (WAIS) changes after levodopa treatment.
J. Beardsley (1971)
Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro.
E. Richelson (1984)
10.1002/ANA.410130116
Decreased pyruvate dehydrogenase complex activity in Huntington and Alzheimer brain
S. Sorbi (1983)
10.1111/j.1471-4159.1982.tb08690.x
Glycine Receptors in the Human Substantia Nigra as Defined by [3H]Strychnine Binding
G. Montis (1982)
10.1212/WNL.44.10.1950
The apolipoprotein E allele epsi;4 is overrepresented in patients with the Lewy body variant of Alzheimer's disease
D. Galasko (1994)
Does stereotactic treatment for Parkinson's disease slow the progression of the disease?
H. Narabayashi (1996)
10.1177/07067437720176S221
Psychiatric Manifestations of Levodopa *
J. A. Yaryura-Tobias (1972)
10.1111/j.1600-0447.1992.tb01473.x
Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double‐blind comparative study
A. Claus (1992)
10.1007/BF02257646
Cholinergic nicotinic and muscarinic receptors in dementia of Alzheimer, Parkinson and Lewy body types
E. Perry (1990)
characteristic of human neurodegenerative diseases
G McKhann (1984)
10.1176/ajp.149.1.138b
Seizure with low doses of clozapine.
P. Thomas (1992)
levodopa-treated Parkinson's disease patients
AAHP Megens (1994)
Parkinsonism exacer
FJ Jimenez-Jimenez (1994)
Neurotransmitter dysfunction and atrophy of the caudate nucleus in Alzheimer's disease.
B. Pearce (1984)
10.1016/0304-3940(94)90666-1
Lewy bodies in the brain of two members of a family with the 717 (Val to Ile) mutation of the amyloid precursor protein gene
P. Lantos (1994)
10.1002/ANA.410360306
Glutathione‐related enzymes in brain in Parkinson's disease
J. Sian (1994)
10.1001/ARCHNEUR.1993.00540020018011
A clinicopathologic study of 100 cases of Parkinson's disease.
A. Hughes (1993)
10.1111/j.1440-1789.1996.tb00152.x
Cerebral type of Lewy body disease
Kenji Kosaka (1996)
10.1016/S0140-6736(89)91187-2
CLINICALLY AND NEUROPATHOLOGICALLY DISTINCT FORM OF DEMENTIA IN THE ELDERLY
R. Perry (1989)
10.1212/WNL.40.10.1523
Antemortem diagnosis of diffuse Lewy body disease
H. Crystal (1990)
10.1016/0022-510X(90)90236-G
Senile dementia of Lewy body type: A clinically and neuropathologically distinct form of Lewy body dementia in the elderly
R. Perry (1990)
10.1016/0163-1047(90)90639-N
Cholinergic-dopaminergic interactions in cognitive performance.
E. Levin (1990)
10.1136/bmj.3.5981.471
Tolerance of debility in elderly dependants by supporters at home: its significance for hospital practice.
J. R. Sanford (1975)
10.1136/jnnp.52.11.1236
Diffuse Lewy body disease: correlative neuropathology using anti-ubiquitin immunocytochemistry.
G. Lennox (1989)
10.1136/jnnp.51.2.244
The effect of age of disease onset on neuropsychological performance in Parkinson's disease.
M. Hietanen (1988)
Implications of alterations in trace element levels in brain in Parkinson's disease and other neurological disorders affecting the basal ganglia.
D. Dexter (1993)
10.1017/S0033291700038484
Operational criteria for senile dementia of Lewy body type (SDLT).
I. McKeith (1992)
Ubiquitin carboxyl
J Lowe (1990)
Different effects of dopaminergic and anticholinergic therapy on memory performance in Parkinson's disease
JA Cooper (1992)
cathepsin 0 in astrocytes
OW Dickson (1989)
Lewy bodies. In: Caine D (ed) Neurodegenerative diseases
J Lowe (1994)
10.1016/S0140-6736(94)91933-X
Tacrine for senile dementia of Alzheimer's or Lewy body type
G. Wilcock (1994)
10.1192/BJP.163.3.364
Neuropathological correlates of behavioural disturbance in confirmed Alzheimer's disease.
Hans Förstl (1993)
10.1093/BRAIN/110.5.1131
Clinical and pathological features of diffuse cortical Lewy body disease (Lewy body dementia).
W. Gibb (1987)
10.1093/BRAIN/112.5.1141
Depression and cognitive impairment in Parkinson's disease.
S. Starkstein (1989)
10.1002/GPS.930050202
Disorders of affect in alzheimer's disease
A. Burns (1990)
10.1016/0006-8993(92)90754-W
Interactions of fluoxetine with metabolism of dopamine and serotonin in rat brain regions
R. Baldessarini (1992)
10.1016/0922-4106(94)90047-7
Clozapine is a potent and selective muscarinic M4 receptor agonist.
S. Zorn (1994)
10.1007/BF00294638
Morphological characteristics of senile plaques in familial Alzheimer's disease
E. Iseki (2004)
10.1007/BF00177743
Novel anxiolytics discriminate between postsynaptic serotonin receptors mediating different physiological responses on single neurons of the rat hippocampus
R. Andrade (2004)
10.1192/BJP.136.3.256
Computed tomography in the elderly. 2. Senile dementia: diagnosis and functional impairment.
R. Jacoby (1980)
10.1111/j.1471-4159.1989.tb11760.x
Reduced Glycine Stimulation of [3H]MK‐801 Binding in Alzheimer's Disease
A. W. Procter (1989)
10.1016/0022-3956(75)90026-6
"Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.
M. Folstein (1975)
10.1136/jmg.32.8.642
Apolipoprotein E epsilon 4 allele is a risk factor for familial and sporadic presenile Alzheimer's disease in both homozygote and heterozygote carriers.
D. St Clair (1995)
10.1016/S0010-9452(84)80051-9
Disturbance of Recent Memory Function in Parkinsonian Patients on Anticholinergic Therapy
W. Koller (1984)
Neuropathology of unusual dementias: an overview.
P. Lantos (1992)
Parkinson's disease: drug-induced psychiatric states.
S. Factor (1995)
10.1097/00002093-199307020-00002
Cholinergic Transmitter and Neurotrophic Activities in Lewy Body Dementia: Similarity to Parkinson's and Distinction from Alzheimer Disease
E. Perry (1993)
10.1212/WNL.44.5.872
An evaluation of the predictive validity and inter‐rater reliability of clinical diagnostic criteria for senile dementia of Lewy body type
I. McKeith (1994)
10.1212/WNL.44.12.2300
Utility of extrapyramidal signs and psychosis as predictors of cognitive and functional decline, nursing home admission, and death in Alzheimer's disease
Y. Stern (1994)
10.1212/WNL.39.9.1219
Clozapine in the treatment of psychosis in Parkinson's disease
J. Friedman (1989)
10.1212/WNL.44.8.1432
Meige syndrome in the spectrum of Lewy body disease
M. Mark (1994)
10.1097/00005053-198608000-00010
Apparent neuroleptic malignant syndrome with clozapine and lithium.
H. Pope (1986)
10.1080/13607869757353
Cholinergic phytochemicals: From magic to medicine
E. Perry (1997)
Diagnostic criteria for dementia associated with corti
M Landon (1991)
[Clinical subtypes of Parkinson's disease].
Y. Mizuno (1993)
10.1038/350610A0
Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine
H. Tol (1991)
10.1002/ANA.410200510
A postmortem study of amino acid neurotransmitters in Alzheimer's disease
D. W. Ellison (1986)
10.1001/ARCHNEUR.1980.00500520053008
Treatment with tryptophan of levodopa-associated psychiatric disturbances.
B. L. Beasley (1980)
10.1093/OXFORDJOURNALS.QJMED.A067623
The impact of treatment with levodopa on Parkinson's disease.
K. Shaw (1980)
10.1016/0140-6736(91)92851-R
Ondansetron in treatment of schizophrenia
A. White (1991)
10.1212/WNL.30.8.820
Presenile Alzheimer disease
J. Pro (1980)
10.1212/WNL.38.10.1520
Diffuse Lewy body disease and progressive dementia
C. Burkhardt (1988)
10.1097/00005072-199601000-00005
Neocortical Lewy Body Counts Correlate with Dementia in the Lewy Body Variant of Alzheimer's Disease
W. Samuel (1996)
10.1136/jnnp.55.3.181
Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.
A. Hughes (1992)
10.1016/0014-2999(76)90340-X
Brain dopamine receptors and sleep in the rat: effects of stimulation and blockade.
S. Kafi (1976)
10.1136/jnnp.54.2.159
Diffuse Lewy body disease presenting with a supranuclear gaze palsy.
J. Fearnley (1991)
Dopamine agonists and sleep in man
C Cianchetti (1985)
10.1097/00002826-199108000-00001
The management of the levodopa psychoses.
J. Friedman (1991)
disease and vascular dementia
S Bodhireddy (1994)
10.1212/WNL.43.11.2227
Risk factors for nursing home placement in advanced Parkinson's disease
C. Götz (1993)
10.1006/SMNS.1995.0020
Living neurochemistry: the dopaminergic system
G. Sawle (1995)
10.1192/BJP.114.512.797
The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects.
G. Blessed (1968)
10.1001/JAMA.1971.03190260031009
Psychiatric side effects of levodopa in man.
F. K. Goodwin (1971)
10.1177/089198878900200406
Personality Alterations in Dementia of the Alzheimer Type: A Three-Year Follow-up Study
S. Petry (1989)
10.1002/MDS.870030209
Meige syndrome: Neuropathology of a case
J. Kulisevsky (1988)
10.1002/ANA.410190307
Regional distribution of amino acid transmitters in postmortem brains of presenile and senile dementia of Alzheimer type
H. Sasaki (1986)
10.1001/ARCHNEUR.1983.04050040033004
A family with histologically confirmed Alzheimer's disease.
L. Nee (1983)
10.1002/ANA.410370120
The CYP2D6B mutant allele is overrepresented in the Lewy body variant of Alzheimer's disease
T. Saitoh (1995)
10.1017/S0317167100047405
Detection of Lewy bodies in Trisomy 21 (Down's syndrome).
R. Raghavan (1993)
10.1111/j.1471-4159.1990.tb04948.x
Enzyme Activities in Relation to pH and Lactate in Postmortem Brain in Alzheimer‐Type and Other Dementias
C. Yates (1990)
10.1111/j.1750-3639.1992.tb00708.x
Hereditary Lewy‐Body Parkinsonism and Evidence for a Genetic Etiology of Parkinson's Disease
R. Duvoisin (1992)
10.1016/0006-3223(88)90022-4
Clozapine and haloperidol in the amygdaloid complex: Differential effects on dopamine transmission with long-term treatment
G. D. Anderson (1988)
The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent.
N. Moore (1992)
10.1056/NEJM199211263272201
Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of patients with Parkinson's disease.
D. Spencer (1992)
New and emerging strategies for improving levodopa treatment.
E. Tolosa (1994)
Motor and mental side effects of clozapine.
J. Gerlach (1994)
10.1212/WNL.42.11.2131
Amyloid angiopathy in diffuse Lewy body disease
E. Wu (1992)
10.1212/WNL.45.1.97
Apolipoprotein E genotype and Lewy body disease
C. Lippa (1995)
Akathisia in idiopathic Parkinson's disease.
A. Lang (1987)
Gordon for neuropathological examinations. Much of the work was conducted at MRC Human Genetics Unit, Edinburgh and supported by The Wellcome Trust
A. Dr (1989)
Cerebellar plaques
B Azzarelli (1992)
Quantification of beta A4 protein deposition
JM Polak (1992)
10.1007/BF02259665
The use of famotidine in the treatment of Parkinson's disease: a pilot study
S. Molinari (1995)
10.1212/WNL.38.6.961
Evidence for a role of haloperidol‐sensitive σ‐'opiate' receptors in the motor effects of antipsychotic drugs
J. M. Walker (1988)
10.1176/AJP.135.1.99
Clozapine plasma levels and convulsions.
G. Simpson (1978)
Amyloid ~-peptide and its relationship with dementia in Parkinson's disease. In: Korczyn AD (ed) Dementia in Parkinson's disease
K Jendroska (1994)
10.1016/0140-6736(93)92594-J
Dopamine D4 receptor subtypes and response to clozapine
S. Shaikh (1993)
Diagnostic criteria for dementia associated with cortical Lewy bodies
E Byrne (1991)
10.1097/00002826-199202001-00267
SYMPTOMATIC RELIEF FROM TREATMENT INDUCED PSYCHOSIS IN PARKINSON'S DESEASE: A PILOT STUDY WITH REMOXIPRIDE
E. Mohr (1992)
1990a) A clinically and neuropathologically distinct form of Lewy body dementia in the elderly
RH Perry (1990)
1995a) A familial Alzheimer's disease locus on chromosome
E Levy-Lahad (1995)
10.1111/j.1471-4159.1988.tb02983.x
Evidence of Glutamatergic Denervation and Possible Abnormal Metabolism in Alzheimer's Disease
A. Procter (1988)
L-dopa therapy in Parkinson's disease: a critical review of nine years' experience.
A. Barbeau (1969)
10.1212/WNL.39.3.438
Dose‐dependent memory impairment in Parkinson's disease
S. Huber (1989)
10.1097/00004714-199502001-00005
Clinical Efficacy of Serotonin‐Dopamine Antagonists Relative to Classic Neuroleptics
R. Borison (1995)
10.1111/j.1471-4159.1987.tb04127.x
Dementia of the Alzheimer's Type: Changes in Hippocampal L‐[3H]Glutamate Binding
J. T. Greenamyre (1987)
Site-specific blockade of dopamine receptors by neuroleptic agents in human brain.
R. Borison (1981)
10.1212/WNL.45.3.461
The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part X. Neuropathology Confirmation of the Clinical Diagnosis of Alzheimer's Disease
M. Gearing (1995)
10.1016/0022-510X(88)90118-9
Topographical distribution of neurochemical changes in Alzheimer's disease
A. Procter (1988)
10.1002/GPS.930061102
F. H. Lewy on Lewy bodies, parkinsonism and dementia
Hans Föorstl (1991)
10.1001/ARCHNEUR.1982.00510220064017
Effects of anticholinergic drugs on memory in Parkinson's disease.
M. Sadeh (1982)
10.1016/0006-8993(90)90733-R
Loss of brainstem serotonin- and substance P-containing neurons in Parkinson's disease
G. Halliday (1990)
10.1007/BF00687434
Juvenile Parkinson's disease with widespread Lewy bodies in the brain
N. Yoshimura (2004)
10.1016/0304-3940(88)90086-9
[3H]MK-801 binding in Alzheimer's disease
M. M. Mouradian (1988)
10.1016/0006-8993(88)90048-0
Regional distribution of pre- and postsynaptic glutamatergic function in Alzheimer's disease
R. Cowburn (1988)
10.1002/GPS.930091107
What is the clinical prevalence of lewy body dementia?
S. Shergill (1994)
10.1159/000107299
Quantitative assessment of the synaptophysin immuno-reactivity of the cortical neuropil in various neurodegenerative disorders with dementia.
S. Zhan (1993)
10.1016/0140-6736(91)92823-K
Apolipoprotein E genotyping by one-stage PCR
P. Wenham (1991)
10.1212/WNL.43.1_PART_1.211
Increase of Parkinson disability after fluoxetine medication.
E. N. Steur (1993)
10.1126/SCIENCE.2218531
Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides.
B. Yankner (1990)
10.1111/j.1471-4159.1989.tb09133.x
Basal Lipid Peroxidation in Substantia Nigra Is Increased in Parkinson's Disease
D. Dexter (1989)
10.1002/1097-4679(197504)31:2<321::AID-JCLP2270310235>3.0.CO;2-1
Cognitive and perceptual effects of long-range L-dopa therapy in Parkinsonism.
A. R. Hamel (1975)
10.1212/WNL.40.5.832
Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis
E. C. Wolters (1990)
10.1016/0022-510X(88)90179-7
A post-mortem study of noradrenergic, serotonergic and GABAergic neurons in Alzheimer's disease
K. Reinikainen (1988)
10.1007/978-3-642-36172-2_200197
Lewy body dementia.
G. Lennox (1992)
10.1136/jnnp.56.6.583
Molecular pathology of Alzheimer's disease.
M. Rossor (1993)
Dopamine D2 receptors in demented patients with severe neuroleptic sensitivity.
M. Piggott (1994)
Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values.
H. Meltzer (1989)
Selective hypometabolism
HS Mayberg (1990)
Amygdala pathology
H Braak (1994)
In cingulate cortex in DLB the levels of iron are increased
Oxidative stress in dementia with Lewy bodies The pathologic volume (1996)
Is hallucinosis
E Melamed (1993)
Transition metals, ferritin, glutathione and ascorbic acid in Parkinson's disease
P Reiderer (1989)
Accuracy of diagnosis of idiopathic
AJ Hughes (1992)
Mitochondrial complex 1 deficiency in Parkinson's disease
A Schapira (1990)
10.1056/NEJM199601113340202
Prevalence of parkinsonian signs and associated mortality in a community population of older people.
D. Bennett (1996)
10.1001/ARCHPSYC.1961.01710120031004
An inventory for measuring depression.
A. Beck (1961)
10.1016/0304-3940(86)90320-4
Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients
T. Perry (1986)
10.1176/AJP.143.6.756
Clinical and biochemical features of depression in Parkinson's disease.
R. Mayeux (1986)
10.1002/MDS.870050310
Clozapine for psychosis in Parkinson's disease
R. Pfeiffer (1990)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar